IN THE half-century which has elapsed since the original description of keratosis blennorrhagica by Vidal1 in 1893, it has become generally agreed that this disease represents a distinct clinical entity. In 1942 Keim2 analyzed the disease from an etiologic standpoint and described the fundamental histologic changes. Since that time numerous investigators have anvanced methods of treatment; these have in the main been directed against the general infection, local treatment proving to be of little value.
Among the therapeutic measures reported favorably are intravenous injections of 1 per cent solution of merbromin N. F., (mercurochromeR), by Willmott3 in 1926, and the use of autogenous vaccines, by Scholtz,4 about one year later. Downing5 reported rapid recovery in a patient following double vesiculectomy and prostatotomy. Sherman, Blumenthal and Heidenreich6 stressed the importance of treating the primary focus and stated the opinion that local treatment of the
THOMPSON RG, WHITE CB, HAILEY H. KERATOSIS BLENNORRHAGICA: Response to Streptomycin; Report of a Case. Arch Derm Syphilol. 1949;59(3):284–292. doi:10.1001/archderm.1949.01520280036004
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.